Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Titre officiel

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Sommaire:

Les médicaments anticancéreux qui ciblent les effets des changements anormaux des gènes sont appelés « traitements ciblés ». Cette étude appelée PM.1 ou CAPTUR comprendra certains traitements ciblés actuellement sur le marché. Le but de cette étude est de connaître les effets sur les patients et leur cancer d’un traitement pharmacologique ciblé administré spécifiquement contre un changement anormal d’un gène lié à leur cancer.

Description de l'essai

Primary Outcome:

• Objective response rate defined as the number of patients with complete response or partial response

Secondary Outcome:

• Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug
• Progression-free survival by disease-appropriate objective criteria

Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumours that might be responsible for their malignant behaviour such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centres and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumours to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumour profiling and have 'druggable' changes identified in their cancers.

Voir cet essai sur ClinicalTrials.gov